Drugs and FDA
Hims & Hers will offer Eli Lilly’s branded obesity drugs
Eligible patients with a prescription can access Zepbound and Foundayo through Hims at Lilly’s self-pay prices.
Eli Lilly will offer its obesity drugs Zepbound and Foundayo through Hims & Hers’ telehealth platform, the companies announced, according to BioPharma Dive. Under the deal, eligible patients with a prescription can use Hims to access the drugs at the same self-pay prices available elsewhere.
Foundayo has an initial price of $149 per month, while Zepbound starts at $299 per month, BioPharma Dive reported. Hims had previously offered compounded versions of GLP-1 weight loss drugs. The outlet reported that the company changed course in March after a legal challenge from Novo, moving to a strategy of providing access to FDA-approved weight loss medicines. Hims struck a similar deal with Novo in March.
